Navigation Links
University of Colorado Cancer Center earns major grant to develop new bladder cancer drugs

Bladder cancer kills by metastasizing usually to the lungs. A major grant from the National Cancer Institute will help the University of Colorado Cancer Center develop new drugs aimed at stopping bladder cancer's spread, which will kill an estimated 15,000 people in the United States this year.

"Strong preliminary work shows specific proteins that bladder cancer cells need in order to leave the bladder and attach to lung tissue. And additional work points to a number of drug candidates that block the activity of these proteins. The current project aims to select the best drug, use medicinal chemistry to boost its effectiveness, and move the optimized drug toward a human clinical trial," says Dan Theodorescu, MD, PhD, director of the University of Colorado Cancer Center, who will co-lead the project with David Ross, PhD, chair of the Department of Pharmaceutical Sciences at the Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of Colorado.

The work is especially important in light of two current conditions: first, the extended absence of new drugs targeting bladder cancer, with the most recent advance being the addition of the drug gemcitabine, which earned FDA approval in 1997; and second, the recent explosion of technologies that allow the development of drugs that target a cancer's specific genetic abnormalities.

"We've seen a paradigm shift toward targeted therapies drugs that unlike the traditional chemotherapies selectively kill cancer cells while leaving healthy tissue unharmed. We hope to apply this paradigm to metastatic bladder cancer," says Colin Dinney, MD, co-principal investigator and chair of the Department of Urology at project partner MD Anderson.

"This project will target metastatic colonization in bladder cancer by targeting the proteins that drive these processes," says David McConkey, PhD, co-principal investigator at MD Anderson.

"We also hope to define the biomarkers of patients likely to respond to the drugs," Theodorescu says. Defining the population most likely to benefit from the new drugs would allow the group to select these patients for Phase I clinical trials the project's intended endpoint.

"We are all hopeful that three years from now, we'll have a drug in clinical trials that prevents or delays the development of metastatic disease high-risk patients following treatment of the primary tumor," Theodorescu says.


Contact: Garth Sundem
University of Colorado Denver

Related medicine news :

1. Hospital of the University of Pennsylvania selected to lead US nurse-training initiative
2. University of Pennsylvania and Novartis form alliance to expand use of personalized T cell cancer therapy
3. Boston University researchers expand synthetic biologys toolkit
4. Canadians super-sizing Canadas Food Guide servings: York University study
5. Tel Aviv University researcher says plants can see, smell, feel, and taste
6. Tel Aviv University research links childhood obesity to cancer risk
7. Marshall University scientist awarded NIH grant for lung cancer research
8. University of Texas Medical Branch to study hospital readmission
9. Oxford University Press acquires joint ownership of Journal of Surgical Case Reports
10. Tannins in sorghum and benefits focus of university, USDA study
11. ASHA grant funds cutting-edge AIDS research at Tel Aviv University
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... ... technology to revolutionize the emergency ambulance transport experience for the millions of people ... how Uber has disrupted the taxi industry through the use of technology. Now, ...
(Date:6/26/2016)... ... , ... PawPaws brand pet supplements owned by Whole Health Supply ... health of felines. The formula is all-natural and is made from Chinese herbs that ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of ... recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at Work ... Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her ... would lash out at his family verbally and physically. , “When something upset him, he ... he would use it. He would throw rocks at my other children and say he ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Research ... World Market for Companion Diagnostic Tests" report to their ... Market for Companion Diagnostics The World Market ... and personalized medicine diagnostics. Market analysis in the report includes ... Test Market (In Vitro Diagnostic Kits) by Region (N. America, ...
(Date:6/23/2016)... , June 23, 2016  MedSource announced ... as its e-clinical software solution of choice.  This ... best possible value to their clients by offering ... The preferred relationship establishes nowEDC as the EDC ... for MedSource,s full-service clients.  "nowEDC has long been ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
Breaking Medicine Technology: